These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27653520)

  • 1. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
    Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
    Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.
    Helmich RC; Thaler A; van Nuenen BF; Gurevich T; Mirelman A; Marder KS; Bressman S; Orr-Urtreger A; Giladi N; Bloem BR; Toni I;
    Neurology; 2015 Jan; 84(4):399-406. PubMed ID: 25540317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
    Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
    Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered intrinsic brain functional connectivity in drug-naïve Parkinson's disease patients with LRRK2 mutations.
    Hou Y; Luo C; Yang J; Ou R; Song W; Chen Y; Gong Q; Shang H
    Neurosci Lett; 2018 May; 675():145-151. PubMed ID: 29567424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
    Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective clinical and DaT-SPECT imaging in premotor
    Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
    Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
    Zhang D; Zhou L; Shi Y; Liu J; Wei H; Tong Q; He H; Wu T
    Mov Disord; 2023 Jan; 38(1):138-142. PubMed ID: 36253640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI.
    Gao L; Gaurav R; Ziegner P; Ma J; Sun J; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Fan Z; Lehéricy S; Wu T
    Sci Rep; 2024 May; 14(1):10621. PubMed ID: 38729969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.
    Jacob Y; Rosenberg-Katz K; Gurevich T; Helmich RC; Bloem BR; Orr-Urtreger A; Giladi N; Mirelman A; Hendler T; Thaler A
    Hum Brain Mapp; 2019 Jun; 40(8):2546-2555. PubMed ID: 30793410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.